# A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

> **NCT06886269** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 8 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** 14C-VX-993

## Key facts

- **NCT ID:** NCT06886269
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-21
- **Primary completion:** 2025-05-17
- **Final completion:** 2025-05-17
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886269, "A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT06886269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*